Firefly Neuroscience, Inc. (AIFF) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped AIFF stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Firefly Neuroscience has a compelling investment thesis due to its proven Phase 3 clinical trial results and FDA Fast Track Designation, suggesting expedited market entry for its Alzheimer's treatment. Despite its small cap and emerging competitive pressures, strategic partnerships and secure funding underscore its resilience and innovative capacity. Analysts are highly optimistic, envisioning substantial upward momentum highlighted by the one-year analyst mean target of $15.75. The saved 1-year distribution is P10 $2.25, P50 $6.5, and P90 $16.8.
Last analyzed · Model: gpt-4o
Firefly Neuroscience, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $2.25 | Pessimistic plausible scenario |
| P50 | $6.5 | Median scenario |
| P90 | $16.8 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
The company has shown substantial momentum with positive clinical trial results and secured funding, alongside analysts' optimism for significant upside potential.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this AIFF analysis generated?
March 16, 2026.
Is this a guaranteed AIFF prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full AIFF stock analysis · AIFF sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.